Biotechnology

CLOUDBREAK-B

CLOUDBREAK-B released FY2025 9 Months Earnings on March 31, 2026 (BJT), with actual revenue of HKD 1.094 M and EPS of HKD -0.6728

CLOUDBREAK-B released FY2025 annual earnings on March 31 (BJT), actual revenue HKD 1.973 M, actual EPS HKD -0.8033

CLOUDBREAK-B released FY2024 Q3 earnings on March 31 (BJT), actual revenue HKD 39.69 M, actual EPS HKD -0.3843

CLOUDBREAK-B released FY2024 Q4 earnings on March 31 (BJT), actual revenue HKD 39.66 M, actual EPS HKD -0.384

CLOUDBREAK-B released FY2025 Q3 earnings on March 31 (BJT), actual revenue HKD 875.55 K, actual EPS HKD -0.3382

CLOUDBREAK-B released FY2025 Q4 earnings on March 31 (BJT), actual revenue HKD 875.22 K, actual EPS HKD -0.3381

CLOUDBREAK-B released FY2024 9-month earnings on March 31 (BJT), actual revenue HKD 39.69 M, actual EPS HKD -1.2442

CLOUDBREAK-B to Release FY2025 Earnings on March 30, 2026 (BJT)

Pullcom Vision Cloud Reaches Settlement With Cedar Wealth To Withdraw Arbitration

PortCon Cloud-B and Its Subsidiary Reach Settlement Agreement with Cedar Wealth Paying $2.22 Million

Adspire Vision-B Submits CBT-009 New Drug Clinical Trial Application

Pulse Cyber Vision-B shareholder deposits stocks with CITIC Securities, Fuchai Holding extends lock-up commitment

PokerVision-B Issues 1.785 Million Shares Under Equity Incentive Plan

Fortus Holdings Extends Lock-Up Period Commitment for Pullcom Eye Cloud-B's Issued Shares

Puckcom Vision Cloud-B Submits CBT-199 New Drug Clinical Trial Application

Cloudbreak USA held a Phase 2 Clinical Trial Meeting with FDA for CBT-004

Cloudbreak USA to Hold Post-Phase 2 Clinical Trial Meeting with FDA

KonSiYun Shares Latest Clinical Progress of CBT-001 and CBT-004 at Ophthalmic Innovation Summit

CLOUDBREAK-B released FY2025 Semi-Annual Earnings on August 29 BJT with actual revenue HKD 0 and actual EPS HKD -0.3346

CLOUDBREAK-B released FY2025 Q2 earnings on August 29 (BJT), actual revenue HKD 109.9 K, actual EPS HKD -0.168

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

159506

520880

513700

02592

Cloudbreak announced its 2025 annual results, with losses narrowing to USD 67.66 million, compared to a loss of USD 99.13 million in the same period last year; the loss per share is USD 0.1. No dividend is declared

AASTOCKS

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

First Trust NYSE Arca Biotech Index Fd

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

"Performance" Cloudbreak's annual loss narrowed to USD 67.66 million

CLOUDBREAK-B stated that the company has reached a settlement agreement with CLOUDBREAK-B Guangzhou and Cedar Wealth. The Shanwei Arbitration Commission recently notified that it has approved Cedar Wealth's withdrawal of the arbitration application, and the arbitration fees related to the arbitration procedure will be borne by Cedar Wealth

CLOUDBREAK: Cedar Wealth's application to withdraw arbitration proceedings has been approved

Cloudbreak Pharma, Inc. announced that the Shanwei Arbitration Commission has approved Cedar Wealth’s request to withdraw arbitration proceedings against the company and its subsidiary, Cloudbreak Guangzhou, following a settlement agreement. Cedar Wealth will cover the arbitration fees, which helps reduce legal uncertainties for Cloudbreak’s shareholders and potential investors. The company will provide further updates as the settlement progresses. Cloudbreak Pharma is a pharmaceutical firm listed on the Hong Kong Stock Exchange, focusing on drug development and healthcare activities in Hong Kong and mainland China.

Tip Ranks

Cloudbreak Pharma Secures Withdrawal of Arbitration in Cedar Wealth Dispute

CLOUDBREAK-B fell 16.88%; Rongchang Biologics fell 1.05%, with a transaction volume of HKD 389 million; Innovent Biologics fell 1.76%, with a transaction volume of HKD 321 million; Kintor Pharmaceutical fell 1.28%, with a transaction volume of HKD 252 million; BeiGene fell 1.05%, with a market value of HKD 305.5 billion

HK Stock Alerts

Hong Kong Stock Movement: CLOUDBREAK-B fell 16.88%, with clear capital flow, volatility attracting market attention!

CLOUDBREAK-B fell 17.51%; BGI Genomics rose 8.57%, with a transaction volume of HKD 494 million; BeiGene fell 3.36%, with a transaction volume of HKD 284 million; Innovent Biologics fell 0.17%, with a transaction volume of HKD 132 million; CanSino Biologics fell 0.08%, with a market value of HKD 118.2 billion

Hong Kong Stock Movement: CLOUDBREAK-B falls 17.51%, facing dual pressure from judicial preservation and lifting of restrictions on stock price

CLOUDBREAK-B fell 20.05%; Kelun-B dropped 1.82%, with a transaction volume reaching HKD 1.101 billion; Innovent Biologics had a transaction volume of HKD 874 million; 3SBio fell 0.36%, with a transaction volume reaching HKD 498 million; BeiGene rose 0.50%, with a market value reaching HKD 307.8 billion

Hong Kong stock movement: CLOUDBREAK-B plummets 20.05%, with judicial preservation and pressure from unlocked shares severely impacting stock price

CLOUDBREAK-B fell 15.18%; Kelun-B fell 1.77%, with a transaction amount reaching HKD 1.052 billion; Innovent Biologics rose 0.39%, with a transaction amount reaching HKD 745 million; 3SBio rose 0.36%, with a transaction amount reaching HKD 444 million; BeiGene rose 0.55%, with a market value reaching HKD 308 billion

Hong Kong Stock Movement: CLOUDBREAK-B fell 15.18%, facing a double blow to its stock price from judicial preservation and lifting of restrictions

06090

02575

06616

02577

02208

02431

01045

09678

01709

BUTONG GROUP(06090) fell 29.62%, with a trading turnover 32.5 Million HKD, and a year-to-date fell 32.3%. XUANZHUBIO-B(02575) fell 19.71%, with a trading turnover 31.9 Million HKD, and a year-to-date fell 25.7%. CLOUDBREAK-B(02592) fell 19.07%, with a trading turnover 38.4 Million HKD, and a year-to-date fell 29.8%.

Top Gainers&Losers

BUTONG GROUP

XUANZHUBIO-B

GLOBAL NEW MAT

INNOSCIENCE

GOLDWIND

MINIEYE

APT SATELLITE

UNISOUND

DL HOLDINGS GP

Top 10 HK Stock Losers (1.5)

CLOUDBREAK-B fell 11.53%; Innovent Biologics rose 6.60%, with a transaction volume of HKD 927 million; 3SBio rose 5.45%, with a transaction volume of HKD 658 million; BeiGene rose 6.02%, with a transaction volume of HKD 580 million; CanSino Biologics rose 3.62%, with a market value of HKD 108.1 billion

Hong Kong Stock Movement: CLOUDBREAK-B fell 11.53%, market concerns arise from the extension of the lock-up period and equity incentives

CLOUDBREAK-B(02592.HK)